Frederic Desdouits
Chief Executive Officer OranoMed
Seminars
Thursday 3rd December 2026
Demonstrating the Clinical Potential of Pb-212 Alpha Therapy: Key Learnings from Phase II AlphaMedix Development
9:00 am
- Presenting Phase II clinical data evaluating the safety, efficacy and therapeutic potential of Pb-212-based targeted alpha therapies
- Exploring how clinical findings are shaping patient selection, dosing strategies and future development decisions
- Examining the key translational and operational learnings generated throughout Phase II development
